A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer
Condition(s):Advanced Biliary CancerLast Updated:March 22, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):Advanced Biliary CancerLast Updated:March 22, 2021Unknown status
Condition(s):Advanced Biliary Tract CancerLast Updated:June 23, 2023Completed
Condition(s):Advanced Biliary Tract CancerLast Updated:April 3, 2023Recruiting
Condition(s):Biliary CancerLast Updated:October 13, 2021Terminated
Condition(s):Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder CancerLast Updated:November 14, 2023Terminated
Condition(s):Biliary Tract NeoplasmsLast Updated:November 18, 2023Not yet recruiting
Condition(s):Advanced Biliary CancerLast Updated:June 13, 2012Completed
Condition(s):Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder CancerLast Updated:January 11, 2022Recruiting
Condition(s):Cholangiocarcinoma; Bile Duct Neoplasm; Biliary Tract MalignancyLast Updated:March 12, 2024Recruiting
Condition(s):Biliary Tract Cancer; Immune Checkpoint Inhibitor; Predictive Cancer ModelLast Updated:February 8, 2024Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.